Michael Jeng

Back to Profile

Publication Details

  • Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia.

    Grace RF, Bennett CM, Ritchey AK, Jeng M, Thornburg CD, Lambert MP, Neier M, Recht M, Kumar M, Blanchette V, Klaassen RJ, Buchanan GR, Kurth MH, Nugent DJ, Thompson AA, Stine K, Kalish LA, Neufeld EJ. Pediatr Blood Cancer. 2012; 58 (2): 221-5

    Treatment choice in pediatric immune thrombocytopenia (ITP) is arbitrary, because few studies are powered to identify predictors of therapy response. Increasingly, rituximab is becoming a treatment of choice in those refractory to other therapies.

    PubMedID: 21674758

Stanford Medicine Resources:

Footer Links: